Pharmena (PHR.WA) Stock Price

Pharmena Price

CLOSED
2.89
​
Market closed

Revenue at Pharmena has contracted by 5.3% per year over the past 19 years to 1.58 M PLN. Earnings per share have grown at 22.4% per year over the last 17 years. For Pharmena, the net margin of -175.6% is down versus -30.2% a few years ago. At today's price the dividend yield works out to roughly 29.41%. The dividend has grown at 20.2% per year over the past 15 years.

Pharmena stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmena business model & stock analysis

Pharmena SA develops and markets products based on 1-MNA, a patented physiological active substance. The company sells Dermena for hair loss, Dermena Plus for dandruff and hair loss, Accos for acne, Allerco for hypo-allergic body care, Thermi for burn and sunburn relief, and Revium for anti-wrinkle treatments. Pharmena collaborates with research centers in Europe, the US, and Canada on multidirectional studies. The company has a wholly owned subsidiary, Cortria Corporation, in the US, and its main shareholder is Pelion SA, with Polska Grupa Farmaceutyczna SA holding a 43.65% stake as of 2011. Pharmena SA's revenue comes from direct sales of its product lines to consumers and healthcare providers. Dermena and Dermena Plus target individuals with hair loss concerns, while Accos and Allerco appeal to those seeking acne and sensitive skin solutions. Thermi serves patients recovering from burns, and Revium attracts customers focused on anti-aging skincare. The company’s research partnerships with European, US, and Canadian institutions support product development and market positioning. The company operates through its subsidiary Cortria Corporation in the US, expanding its market reach. Polska Grupa Farmaceutyczna SA, a significant shareholder, likely influences strategic decisions. Pharmena’s product portfolio is structured around specific health and beauty segments, with Dermena and Revium targeting cosmetic and dermatological needs, and Thermi addressing medical recovery applications.

Frequently asked questions about Pharmena

Converted at the current exchange rate, the Pharmena share trades at 0.66 EUR (2.89 PLN).

The revenue cannot currently be calculated for Pharmena.

The profit cannot currently be calculated for Pharmena.

The P/E ratio cannot be calculated for Pharmena at the moment.

The P/S cannot be calculated for Pharmena currently.

The Eulerpool Quality Score for Pharmena is 4/10.

The ISIN of Pharmena is PLPHRMN00011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Pharmena is PHR.WA. The ticker symbol is used to trade Pharmena shares on the stock exchange.

Fair ValueTerminal
2.66 PLN
Over-/UndervaluationTerminal
Fairly valued
Industry
Personal Care Products
Number of shares
Employees
Revenue per Employee
65,708.33 PLN
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website pharmena.eu
Country
Poland
Currency
PLN
Initial public offering
Aug 25, 2008
ISIN
PLPHRMN00011
Cusip
X6453L106
Market capitalization
32.19 M PLNMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
3.34
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-27.65 %
Dividend
Dividend yield
0.00 %
Payout Ratio
182.20 %
Dividend growth Ø5Y
20.79 %
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
19.00 %
Last updated Nov 5, 2026, 3:40 AM

Pharmena Peer Group

Pharmena FIGI

PHR:PW · BBG000BLWRR6PHRPLN:XS · BBG00PPZCT20PHRPLN:XH · BBG00PPZCT57PHRPLN:XF · BBG00PPZCT75PHRPLN:XD · BBG00PPZCT84PHRPLN:XE · BBG00PPZCT93PHRPLN:XJ · BBG00PPZCTB0PHRPLN:XL · BBG00PPZCTC9PHRPLN:XG · BBG00PPZCTD8PHRPLN:XO · BBG00PPZCTF6PHRPLN:XN · BBG00PPZCTG5PHRPLN:XA · BBG00PPZCTK0

All fundamentals and in-depth analysis of Pharmena

Our stock analysis for Pharmena stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmena. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.